Skip to main content

Amifampridine Disease Interactions

There are 3 disease interactions with amifampridine.

Major

Amifampridine (applies to amifampridine) seizures

Major Potential Hazard, Moderate plausibility.

Amifampridine is contraindicated in patients with a history of seizures. Seizures have been observed in patients without a history of seizures at the recommended doses. Seizures may be dose-dependent. Consider discontinuation or dose-reduction in patients who have a seizure while on treatment.

References

  1. (2018) "Product Information. Firdapse (amifampridine)." Catalyst Pharmaceuticals, Inc.
Moderate

Amifampridine (applies to amifampridine) liver disease

Moderate Potential Hazard, Moderate plausibility.

Amifampridine is extensively metabolized by N-acetyltransferase 2 (NAT2) and hepatic impairment may cause an increase in exposure. The effects of amifampridine have not been studied in patients with hepatic impairment. It is recommended to start treatment with amifampridine in patients with any degree of hepatic impairment at the lowest recommended starting dosage (15 mg/day) and monitor for adverse reactions. Consider dosage modification or discontinuation in patients with hepatic impairment as clinically appropriate.

References

  1. (2018) "Product Information. Firdapse (amifampridine)." Catalyst Pharmaceuticals, Inc.
Moderate

Amifampridine (applies to amifampridine) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

Renal clearance is an elimination pathway for amifampridine and the inactive metabolite, 3-N-acetyl amifampridine, and exposure of amifampridine is higher in subjects with renal impairment. Patients with renal impairment should be initiated at the lowest recommended starting dosage (15 mg/day), and patients should be closely monitored for adverse reactions. Consider dosage modification or discontinuation in patients with renal impairment as clinically appropriate. Caution is recommended as the safety, efficacy, and pharmacokinetics of amifampridine have not been studied in patients with end-stage renal disease. No dosage recommendation can be made for patients with end-stage renal disease.

References

  1. (2018) "Product Information. Firdapse (amifampridine)." Catalyst Pharmaceuticals, Inc.

Amifampridine drug interactions

There are 199 drug interactions with amifampridine.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer